Tolemy Bio

Tolemy Bio Ltd, based in the United Kingdom, specializes in advanced biotechnology solutions, particularly in precision medicine and genomics, providing innovative tools for genetic analysis and personalized healthcare. Founded in 2024 and headquartered in Cambridge, UK, Tolemy Bio Ltd focuses on developing biotechnology solutions centered around precision medicine. The company has successfully completed one deal and on May 12, 2026, raised EUR 1. 4 million in pre-seed funding led by Norrsken Evolve, with participation from Big Sur Ventures, JME Ventures, Masia, and a Stealth PE fund.

The funding will support Tolemy Bio's initiatives and enhance its operational capabilities. Tolemy Bio specializes in advanced biotechnology solutions, focusing primarily on precision medicine and genomics. Their core product offerings include a suite of bioinformatics tools and platforms designed to analyze genetic data, enabling healthcare professionals to generate personalized treatment plans. These tools function by integrating and interpreting complex biological information, helping to address critical challenges in disease management and patient care.

Their services target hospitals, research institutions, and pharmaceutical companies, aiming to improve outcomes for patients with chronic illnesses and genetic disorders. The company operates primarily in North America and Europe, with a growing client base that includes both public and private healthcare providers, as well as research organizations interested in leveraging genomic insights for innovative therapies. Tolemy Bio's revenue model is structured around a B2B framework, where they engage in partnerships with healthcare providers and research institutions for direct access to their bioinformatics tools. Transactions typically involve licensing agreements for their software platforms, which may include subscriptions or one-time fees for access to specific features and services.

The company offers tiered pricing plans based on the scale of use, allowing clients to select packages that cater to their unique needs, particularly for flagship products that support genomic analysis and reporting. This transaction structure facilitates ongoing collaboration with clients to ensure that their evolving needs in precision medicine are met. Tolemy Bio plans to leverage the recent funding of EUR 1. 4 million to advance its AI-enabled cell biology platform, enhance data generation capabilities, and support early customer and partner deployments.

The company is also focused on expanding its market reach in Europe and North America, with initiatives aimed at launching new products tailored for the healthcare sector by the end of 2026.